Abstracts tagged "IL-6"

Abstract Number: 1426 • 2015 ACR/ARHP Annual Meeting
The Effect of Anti-Interleukin-6 Receptor Antibody in Ovariectomized Mice
Sho Kato¹, Hiroki Wakabayashi², Taro Nakagawa³, Yohei Naito³, Takahiro Iino⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ²Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ³Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁴Mie University Graduate School of Medicine, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁵Orthopaedic surgery, Mie University Postgraduate School of Medicine, Tsu-city, Japan
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague low back pain. Bone pain associated with bone metastasis may also be related to…
Abstract Number: 1530 • 2015 ACR/ARHP Annual Meeting
Neutrophil Function and Survival Unaffected in Healthy Subjects Following Single Administration of Tocilizumab
Laurence Lok¹, Jatinder Juss¹, Neda Farahi¹, Chrystalla Loutsios¹, Chandra Solanki², Adrien Michael Peters³, Sophie Dimonaco⁴, Francis Donaldson⁴, Benjamin Porter-Brown⁴ and Edwin Chilvers¹, ¹Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ²Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, United Kingdom, ³Division of Clinical and Laboratory Investigation, Brighton and Sussex Medical School, Brighton, United Kingdom, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Decreases in circulating neutrophil counts have been observed in adults with rheumatoid arthritis (RA) and children with systemic or polyarticular juvenile idiopathic arthritis treated…
Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting
Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting
Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Vibeke Strand¹, Annette Diehl², Jared Christensen², Joseph Wajdula², Sudhakar Sridharan³ and Paul J Healey², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, New York City, NY, ³PPD Inc, Rockville, MA
Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…
Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting
The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice
Jennifer L. Auger¹, Brianna J. Engelson², Yaya Wang³, Erik J. Peterson⁴ and Bryce A. Binstadt⁵, ¹Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ²Pediatrics, University of Minnesota, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
Abstract Number: 1014 • 2014 ACR/ARHP Annual Meeting
Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes
Abdul Haseeb¹ and Tariq Haqqi², ¹Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH, ²Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH
Background/Purpose: There is growing evidence that shows the involvement of IL-6 in cartilage degradation during OA. Significant correlation between IL-6 levels in serum as well…
Abstract Number: 2877 • 2014 ACR/ARHP Annual Meeting
Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Jun Kikuchi², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose The immunological roles of interleukin 27 (IL-27) have been reported in the function of regulatory T cells (Treg), monocytes and osteoclasts, and these cells…
Abstract Number: 952 • 2014 ACR/ARHP Annual Meeting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis
Philip J. Mease¹, A B Gottlieb², A Berman³, E Drescher⁴, J Xing⁵, S Banerjee⁵ and R Wong⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁴Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: New treatment options for psoriatic arthritis (PsA) are needed and interleukin-6 (IL-6), a cytokine with a central role in chronic inflammation, is a potential…
Abstract Number: 2823 • 2014 ACR/ARHP Annual Meeting
Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Roy Fleischmann^1,2, Dennis L. Decktor³, Chunpeng Fan⁴, Hubert Van Hoogstraten⁵ and Mark C Genovese⁶, ¹Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Biostatistics, Sanofi, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose For patients with prior exposure to tumor necrosis factor-α inhibitor (TNF-I), the likelihood of response to subsequent treatment with a TNF-I declines with the…
Abstract Number: 784 • 2014 ACR/ARHP Annual Meeting
Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1
Jason Springer¹, Vineesh Raveendran², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan², ¹Department of Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose Early in the pathogenesis of Giant Cell Arteritis (GCA) dendritic cells interact with T cells of both Th1 and Th17 origin. IL-6; released by…
Abstract Number: 2824 • 2014 ACR/ARHP Annual Meeting
A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Arthur Kavanaugh¹, Dennis L. Decktor², Chunpeng Fan³, Janet van Adelsberg², Renata Martincova⁴ and Mark C. Genovese⁵, ¹University of California San Diego, La Jolla, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Biostatistics, Sanofi, Bridgewater, NJ, ⁴Sanofi Czech Republic, Prague, Czech Republic, ⁵Stanford University Medical Center, Palo Alto, CA
Background/Purpose Interleukin-6 (IL-6) regulates a diverse array of activities that may underlie systemic and local symptoms of rheumatoid arthritis (RA). The efficacy of sarilumab, a…
Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs
Thomas Dörner¹, Hans-Peter Tony², Gerd Burmester¹, Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kästner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, Sylke Wagner⁸, Marvin A. Peters⁹ and Christoph Iking-Konert¹⁰, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University Clinic Wuerzburg, Wuerzburg, Germany, ³University Clinic Munich, Munich, Germany, ⁴Rheumatology Practice, Ludwigsfelde, Germany, ⁵MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, ⁶Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, ⁷Rheumatology Practice, Aachen, Germany, ⁸Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰University Clinic Hamburg-Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting
Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Anita Boyapati¹, Jérôme Msihid², Emmanuelle Cousin³, Ling Cai⁴, Janet van Adelsberg¹, Jennifer D Hamilton¹, Neil Graham⁵, Tanya Momtahen⁶ and Stefano Fiore⁷, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi R&D, France, Chilly-Mazarin, NJ, France, ³Sanofi R&D, France, Chilly-Mazarin, France, ⁴Sanofi R&D, China, Beijing, China, ⁵Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Sanofi, Bridgewater, NJ, ⁷Distinct Project Unit, Sanofi, Bridgewater, NJ
Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…
Abstract Number: 332 • 2014 ACR/ARHP Annual Meeting
Improvement of the Stability of RNA Aptamers Against Interleukin-17A
Natsuki Otaki¹, Asako Sasaki¹, Shinsuke Hiramoto¹, Masakazu Nagamine¹, Shigeyuki Mori¹, Tomoyoshi Kayo¹, Kuniyoshi Hota¹, Masayuki Takahashi¹, Kazuhiko Haruta² and Yoshikazu Nakamura^3,4, ¹Zenyaku Kogyo Co., Ltd., Tokyo, Japan, ²2-33-7 Oizumi, Nerima, Zenyaku Kogyo Co., Ltd., Tokyo, Japan, ³Division of RNA Medical Science, The Institute of Medical Science, The University Of Tokyo, Tokyo, Japan, ⁴RIBOMIC Inc., Tokyo, Japan
Background/Purpose Aptamers are RNA or DNA oligonucleotides selected for their capacity to specifically bind and inhibit the function of a target protein. The effect is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].